Long-term efficacy and toxicity of cyclosporin A + fluocortolone + methotrexate in the treatment of rheumatoid arthritis

Clinical and Experimental Rheumatology

Volumn 17, Issue 6, 1999, Pages 679-688

  Pascalis, L ^a   Aresu, G ^a   Pia, G ^a  

^a UNIVERSITY OF CAGLIARI   (Italy)

Author keywords

Cyclosporin A; Fluocortolone; Methotrexate; Rheumatoid arthritis

Indexed keywords

CYCLOSPORIN A; FLUOCORTOLONE; METHOTREXATE;

ADOLESCENT; ADULT; AGED; ARTICLE; CARTILAGE DEGENERATION; CREATININE BLOOD LEVEL; DOSE RESPONSE; DRUG EFFECT; DRUG EFFICACY; DRUG TOLERABILITY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; NEPHROTOXICITY; OSTEOLYSIS; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; RIGIDITY;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; CREATININE; CYCLOSPORINE; DISEASE PROGRESSION; DRUG THERAPY, COMBINATION; FEMALE; FLUOCORTOLONE; GLUCOCORTICOIDS; HUMANS; JOINTS; KIDNEY; MALE; METHOTREXATE; MIDDLE AGED; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 0032751630     PISSN: 0392856X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (51)

1. HARRIS ED JR: Clinical features of rheumatoid arthritis. In KELLY WN, HARRIS ED JR, RUDDY S, and SLEDGE CB (Eds.): Textbook of Rheumatology. 4th ed., vol. 1, Philadelphia, W.B. Saunders, 1993: 874-911.
2. PINCUS T, CALLAHAN LF: What is the natural history of rheumatoid arthritis? Rheum Dis Clin North Am 1993; 19: 123-51.
3. BUCHT A, OKSENBERG JR, LINDBOLD S, GRONBERG A, STEINMAN L, KLARESKOG L: Characterization of T-cell receptor repertoire in synovial tissue from different temporal phases of rheumatoid arthritis. Scand J Immunol 1992; 35: 159-63.
4. HOWELL MD, DINELY JP, LUNDEN KA: Limited T-cell receptor b-chain heterogeneity among interleukin-2 receptor-positive synovial T-cell suggest a role for superantigen in rheumatoid arthritis. Proc Nat Acad Sci USA 1991; 88: 10921-7.
5. PANAYI GS: The immunopathogenesis of rheumatoid arthritis. Br J Rheumatol 1993; 32 (Suppl. 1): 4-14.
6. EPSTEIN FH: Rheumatoid arthritis: Pathophysiology and implications for therapy. N Engl J Med 1990; 322: 1277-88.
7. LANDEWE RBM, GOEI THE HS, van RIJTHOVEN AWAM, RIETVELD JR, BREEDVELD FC, DIJKMANS BAC: Cyclosporine in common clinical practice: An estimation of the benefit/risk ratio in patients with rheumatoid arthritis. J Rheumatol 1994; 21: 1631-6.
8. FØRRE Ø and the Norwegian Arthritis Study Group: Radiologic evidence of disease modification in rheumatoid arthritis patients treated with cyclosporine. Arthritis Rheum 1994; 37; 1506-12.
9. LOWE NJ: Systemic treatment of severe psoriasis. The role of cyclosporine. N Engl J Med 1991; 324: 277-84.
10. BOREL JF: Mechanism of action of cyclosporin A and rationale for use in nephrotic syndrome. Clin Nephrol 1991; 35 (Suppl. 1): 523-30.
11. SANDBORN WJ, TREMAINE WJ: Cyclosporin treatment of inflammatory bowel disease. Mayo Clin Proc 1992; 67: 981-90.
12. PASCALIS L, PIA G, ARESU G, FRONGIA T, BARCA L: Combined cyclosporin A-steroid-MTX treatment in endogenous non-infections uveitis. J Autoimmunity 1993; 6: 467-80.
13. LUQMANI R, GARSON C, BACON P: Clinical pharmacology and modification of autoimmunity and inflammation in rheumatoid disease. Drugs 1994; 47: 259-85.
14. RUSSELL RGG, GRAVELEY R, SKJODTH: The effect of Cyclosporin A on bone and cartilage. Br J Rheumatol 1993; 32 (Suppl. 1): 42-6.
15. RAU R, SCHLEUSSER B et al.: Longterm treatment of destructive rheumatoid arthritis with methotrexate. J Rheumatol 1997; 24: 1981-9.
16. PINCUS T, CALLAHAN LF: Remodeling the pyramid or remodeling the paradigms concerning rheumatoid arthritis - Lesson from Hodgkin's disease and coronary artery disease. J Rheumatol 1990; 17: 1582-5.
17. FELSON DT, ANDERSON JJ, MEENAN RF: The efficacy and toxicity of combination therapy in rheumatoid arthritis: A meta-analysis. Arthritis Rheum 1994; 37: 1487-91.
18. TUGWELL P, PINCUS T, YOCUM D: Combination therapy with cyclosporine and methotrexate in severe rheumatoid arthritis. N Engl J Med 1995; 333: 137-41.
19. STEIN CM, PINCUS T, YOCUM D: Combination treatment of severe rheumatoid artritis with cyclosporine and methotrexate for forty-eight weeks. Arthritis Rheum 1997; 40: 1843-51.
20. PIA G, PASCALIS L, ARESU G, ROSETTI L, LEDDA MA: Evaluation of the efficacy and toxicity of the Cyclosporine A. Sarcoidosis 1996; 13: 146-52.
21. ARNETT FC, EDWORTHY SM, BLOCH DA et al.: The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988; 31: 315-24.
22. STEINBROCKER O, TRAEGER CH, BATTERMAN RC: Therapeutic criteria in rheumatoid arthritis. JAMA 1949; 140: 315-24.
23. MIESCHER PA, BERIS PH: Immunosuppressive therapy in the treatment of autoimmune diseases. Springer Semin Immunopathol 1984; 7: 69-72.
24. MIESCHER PA, HUANG YP, ZUBLER RH: New approaches to the treatment of rheumatoid arthritis. Springer Semin Immunopathol 1988; 11: 1-12.
25. RITCHIE DM, BAYLE J, McINNES J, GRIEVESON P, BUCHANAN W: Clinical studies with an articular index for the assessment of joint tenderness in patients with rheumatoid arthritis. Q J Med 1968; 37: 393-406.
26. LEE P, JASANI MK, DICK WC, BUCHANAN W: Evalution of a functional index in rheumatoid arthritis. Scand J Rheumatol 1973;2:71-7.
27. HUSKISSON EC: Measurement of pain. J Rheumatol 1982; 5: 768-69.
28. DONATSCH P, ABISCH E, HOMBERGER M, TROBER R, TRAPP M, VOGES RA: Radioimmunoassay to measure cyclosporin A in plasma and serum samples. J Immunoassay 1981; 2: 19-23.
29. LARSEN A: Radiological grading of rheumatoid arthritis: An interobserver study. Scand J Rheumatol 1973; 2: 136-8.
30. RUSSELL G, GRAVELY R, SEID J, AL-HUMIDAN AK, SKJODT H: Mechanism of action of cyclosporin and effects on connective tissues. Semin Arthritis Rheum 1992; 21 (Suppl. 3): 16-22.
31. FERRACCIOLI GF: Radiographic assessment of rheumatoid arthritis. Controversies an perspectives. Clin Exp Rheumatol 1990;8:529-30.
32. FUCHS HA, PINCUS T: Radiographic damage in rheumatoid arthritis: Description by nonlinear models. J Rheumatol 1992; 19: 1655-8.
33. KUPPER IH, VAN LEEUWEN MA, VAN RIEL PLCM, SLUITER WJ, HOUTMAN NM, CATS HA, VAN RIJSWIJK MH: Influence of a ceiling effect on the assessment of radiographic progression in rheumatoid arthritis during the first 6 years of disease. J Rheumatol 1999; 26:268-76.
34. TUGWELL P, BOERS M: Long-acting drug combinations in rheumatoid arthritis: Updated overiew. In WOLFE F and PINCUS T (Eds.): Rheumatoid Arthritis: Pathogenesis, Assessment, Outcome, and Treatment. New York, Marcel Dekker 1994: 357-71.
35. BENSEN W, TUGWELL P, ROBERTS R: Combination therapy of Cyclosporine with methotrexate and gold in rheumatoid arthritis (2 pilot studies). J Rheumatol 1994; 21: 2034-8.
36. KREMER JM, PETRILLO GF, LAWRENCE DA: Methotrexate (MTX) induces significant changes in IL-1, IL-2, IL-6, and IL-8 but not lymphocyte markers in patients (pts) with rheumatoid arthritis (RA). Arthritis Rheum 1993; 36 (Suppl.): S77 (abstract).
37. RUSSELL RGG, GRAVELEY RM, COXON F: Cyclosporin A. Mode of action and effects on bone and joints tissue. Scand J Rheumatol 1993; 32 (Suppl. 1): 42-52.
38. LANDEWÉ RBM, MILTENBURG AMM, BREEDVELD FC, DAHA MR, DIIJKMANN BAC: Cyclosporine and chloroquine synergistically inhibit the interferon-gamma production by CD4 positive and CDS positive synovial T cell clones derived from a patient with rheumatoid arthritis. J Rheumatol 1992; 19: 1353-7.
39. TUGWELL P: Cyclosporin in the treatment of rheumatoid arthritis. J Autoimmunity 1992; 5 (Suppl. A): 231-40.
40. LANDEWÉ RBM, GOEI THE HS, VAN RIJTHOVEN AWAM, BREEDVELD FC, DIJKMANS BAC: A randomized, double bind, 24-week controlled study of low dose cyclosporine versus chloroquine for early rheuma-toid arthritis. Arthritis Rheum 1994; 37: 637-43.
41. WEINBLATT ME, KAPLAN H, GERMAIN BF: Methotrexate in rheumatoid arthritis: A five-year prospective multicenter trial. Arthritis Rheum 1994; 37: 1994-2002.
42. KAMEL OW, VAN DE RIYN M, LEBRUN DP, WEISS LM, WARNAKE RA, DORFMAN RF: Lymphoid neoplasms in patients with rheumatoid arthritis and dermatomyositis: Frequency of Epstein-Barr virus and other features associated with immunosuppression. Hum Pathol 1994; 25: 638-43.
43. FERRACCIOLI GF, CASATTA L, BARTOLI E: Epstein-Barr virus-associated Hodgkin's lymphoma in a rheumatoid arthritis patient treated with methotrexate and cyclosporin A. Arthritis Rheum 1995; 38: 867-8.
44. KWONG YL, AU WY, LIANG RH: Acute myeloid leukemia after azathioprine treatment for autoimmune diseases: Associaton with -7/7q. Cancer Genet Cytogenet 1998; 104: 94 -7.
45. ARNOLD M, SCHRIEBER L, BROOKS P: Immunosuppressive drugs and corticosteroids in the treatment of rheumatoid arthritis. Drugs 1988; 36: 340-63.
46. BAECKLUND E, EKBOM A, SPAREN P, FELTELIUS N, KLORESCKOG L: Disease activity and risk of lymphoma in patients with rheumatoid arthritis: Nested case-control study. BMJ 1998; 317: 180-1.
47. ARELLANO F, KRUPP P: Malignancies in rheumatoid arthritis patients treated with cyclosporin A. Br J Rheumatol 1993; 32 (Suppl. 1): 72-5
48. ZWANENBURG TSB, SUTER W, MATTER BE: Absence of genotoxic potential for Sandimmun in experimental systems. Transpl Proc 1988; 20 (Suppl. 3): 931-3.
49. MIESCHER PA, FAVRE A, LEMOINE R: The place of cyclosporin in the treatment of rheumatoid arthritis. In BONOMO L (Ed.): Cyclosporin in Autoimmune Diseases. Rome, Il Pensiero Scientifico Editore 1990: 119-32.
50. DIJKMANS BA: Safety aspects of cylosporin in rheumatoid arthritis. Drugs 1995; 50 (Suppl. 1): 41-7.
51. ABRAMCZUK A KOHLER CO, ENGELMANN A, BACK D, OPELZ G: Influence of blood transfusions and imunosuppressive therapy on malignancies in renal transplant recipients. In SCHMAHL D and PENN I (Eds.): Cancer in Organ Transplant Recipients, Proceedings, Heidelberg, 28-29 May 1990. Berlin, Springer 1991; 132-8.